HEARTBiT: A Breakthrough Transcriptomic Biomarker for Early Detection of Acute Cellular Rejection Post-Heart Transplantation

MedXY Editorial Team•Oct 3, 2026•Cardiology

HEARTBiT, a blood-based transcriptomic biomarker, reliably detects moderate-to-severe acute cellular rejection (ACR) after heart transplantation across the first post-operative year.
The biomarker maintains high diagnostic accuracy early post-transplant (≤60 days) when rejection risk is greatest, showing an AUC of 0.78 and sensitivity up to 89%.
HEARTBiT enables safe reduction of invasive endomyocardial biopsies, sparing over 50% of routine surveillance biopsies without significantly increasing missed rejection cases.
Serial tracking of HEARTBiT scores demonstrates prognostic potential by rising weeks before histological biopsy detection of rejection, enabling earlier intervention possibilities.

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

HEARTBiT, a blood-based transcriptomic biomarker, reliably detects moderate-to-severe acute cellular rejection (ACR) after heart transplantation across the first post-operative year.
The biomarker maintains high diagnostic accuracy early post-transplant (≤60 days) when rejection risk is greatest, showing an AUC of 0.78 and sensitivity up to 89%.
HEARTBiT enables safe reduction of invasive endomyocardial biopsies, sparing over 50% of routine surveillance biopsies without significantly increasing missed rejection cases.
Serial tracking of HEARTBiT scores demonstrates prognostic potential by rising weeks before histological biopsy detection of rejection, enabling earlier intervention possibilities.